Lead Sponsor

Pfizer

Collaborators

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

•Healthy male and/or female (non-childbearing potential) subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
•Prothrombin time (PT)/INR, and partial thromboplastin time (PTT).
•Plasma Protein C and Protein S activity (functional) within the normal reference range.

•A known sensitivity or previous intolerance to Dimebon or warfarin.
•Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening.
•Subjects receiving warfarin for treatment of active thromboembolic events (ie, pulmonary embolism, deep vein thrombosis), as well as subjects anticoagulated with prosthetic heart valves.

Related studies

NCT05592678 · Alzheimer's Disease (AD), Dementia, and more

NCT07033494 · Early Alzheimer's Disease

NCT06159673 · Alzheimer's Disease Psychosis

NCT07457138 · Subjective Cognitive Decline (SCD), Functional Cognitive Disorder, and more

NCT07422857 · Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects